Record number of reporters jailed globally: Report

ADDIS ABABA, Ethiopia (AP) — The Committee to Protect Journalists says more journalists around the world are sitting in prisons than ever before.

The U.S.-based group on Tuesday said Turkey, Iran and China have imprisoned the most journalists. The journalists' group says that such states are using stepped-up anti-terror and anti-state charges to silence critical reporters.

The Committee to Protect Journalists says it has identified 232 writers, editors, and photojournalists behind bars as of Dec. 1, an increase of 53 from 2011 figures. The 232 number is a record high since the group began its yearly tally in the 1990s.

CPJ Executive Director Joel Simon said anti-state charges and "terrorist" labels have become the preferred means that governments use to intimidate and detain journalists.

Read More..

The CIA Agent Who Found Bin Laden Is Having Trouble at Work

If you're not already aware of the bull-headed CIA agent whose persistent pressure to track Al Qaeda couriers helped lead the way to bin Laden's compound, you're about to be. The main character of Zero Dark Thirty, the soon-to-be released Oscar bait that portrays the story of the Bin Laden raid, is based on said agent, "is based on a real person" whose identity remains classified as she's still working for the CIA. Things at Langley haven't been going so well for said secret, soon-to-be an anonymous celebrity spy, though. In fact, according to a new Washington Post report, things sound like they're going pretty poorly. She's been passed over for a promotion, pissed off all her coworkers and sounds generally unpopular.

RELATED: New York Times Reporter Ran a Maureen Dowd Column by the CIA

The scenario sounds like a plot line from Homeland. (Actually, it sounds like the plot line from Homeland, but that's another blog post for another day.) The anonymous agent, a woman in her mid-30s, got her start as a "targeter," someone who recruits spies or identifies targets for drone strikes. She's known for being uniquely dedicated to her work, the type that stands up for an idea before anyone else is even giving it consideration. Such was the idea to hawk Bin Laden's couriers, and one of her follow officers told The Post that she "was one of the people from very early on pushing this." If you watch the trailer for Zero Dark Thirty, you'll catch a mention of this point. A Navy SEAL asks his teammate why he believes the story behind their next mission, a mission to kill Osama bin Laden, and the teammate answers, "Her confidence," pointing to the character based on this CIA agent.

RELATED: On His Way Out, Arthur Brisbane Rebukes The New York Times Again

It shouldn't be too much of a surprise that this agent's stubbornness and imminent fame is a sensitive issue with her colleagues. After the successful raid, this agent and a few others were awarded the CIA's highest honor for non-combat officers, the Distinguished Intelligence Medal. Instead of congratulating her coworkers, she hit reply-all on an email to the recipients and said that only she deserved the award, since everybody else tried to get in her way when she knew she was right. (Homeland fans, just imagine every scene with Carrie and her bosses, ever.) Around the same time and for unknown reasons, the agent was passed over for a promotion that could've brought her an extra $16,000 a year in income, though she did receive a cash reward of an undisclosed amount for her work on the bin Laden case.
Read More..

Life imitates art: Man strips at Austrian exhibition of paintings and sculptures of naked men

VIENNA - An Austrian museum says a man took the concept of life imitating art to an extreme when he suddenly stripped at an exhibition of pictures and sculptures portraying nude men through the ages.

Vienna's Leopold Museum says that after taking his clothes off, the man calmly sauntered through the exhibition, dressing again only after a security guard asked him to do so.

Museum spokesman Klaus Pokorny said Tuesday that the museum had nothing to do with Saturday's strip, describing it as a "spontaneous act." He says other visitors did not appear disturbed.

He said that since its Oct. 19 opening, the "Nude Men" exhibition had attracted more than 65,000 visitors — all of them dressed except for one.

Read More..

S. Africa, Vietnam sign rhino protection agreement

JOHANNESBURG (AP) — South Africa says its diplomats have signed an agreement with Vietnam to try and halt the trade of horns taken from poached rhinoceros.
South Africa's Department of Environmental Affairs announced Monday that the deal had been signed. The department said the agreement included conservation and protection provisions, as well as a promise to increase law enforcement efforts and information sharing between the two countries.
The deal comes amid a wholesale slaughter of rhinos in South Africa, which has the continent's biggest rhino population. Government statistics released Monday show at least 618 rhinos have been poached this year alone.
Vietnam is one of the top markets for rhino horn. The material is more valuable than cocaine there and is used as a medical supplement, though doctors say it has no benefit.

Read More..

Smart Cups Detect Date Rape Drugs

Drink Savvy, a Boston-based company, has created a material that changes color when it comes in contact with a drug-spiked drink.

Founder Mike Abramson said he plans to use the discovery to create a set of products, including cups, glassware, stirrers and straws, that he hopes will be used to help reduce date rape.

"Within the past three years, three of my very close friends and myself have been the unwitting victims of being drugged," Abramson said in a fundraising video.

The company is trying to raise $50,000 so it can produce the cups and straws and begin selling them online, according to a fundraising appeal posted on the website Indiegogo.

Date rape drugs, including the three most common, GHB, Ketamine and Rohypnol, are odorless, colorless and tasteless, according to the National Institute on Drug Abuse, making them difficult to detect.

Abramson estimates that more than a million people every year are drugged and sexually assaulted. In the video he said he hopes his product will "prevent someone you care about from possibly being the victim of drug-facilitated sexual assault."

Last year, Israeli scientists announced the development of a sensor that looks like a straw or a stirrer that can detect two of the most commonly used date rape drugs with 100 percent accuracy.
Read More..

Lilly tests therapy to rid brain plaques in mice with Alzheimer's

(Reuters) - Drugmaker Eli Lilly  & Co said it may have found a way to remove plaque from the brains of forgetful, old mice using an experimental therapy it hopes someday will be used to treat Alzheimer's disease in humans.

Previous animal studies have demonstrated that it is possible to prevent the formation of brain plaques, which are thought to be a hallmark of the progressive memory-robbing disease. But until now, researchers have not been able to remove pre-existing plaques, made of amyloid beta protein, once they have deposited into the brain, Lilly said.

These deposited plaques are insoluble, whereas soluble forms of amyloid beta are free-floating around the brain and have been easier to target.

Lilly researchers developed a genetically engineered antibody that selectively targets insoluble plaques and was able to cross the blood-brain barrier. The antibody was then able to bind itself to the deposited amyloid beta, and clear roughly 50 percent of pre-existing plaques in the mice without causing damage to tiny vessels in the brain.

"We're very enthused about understanding the mechanism and science behind it," lead researcher Ronald DeMattos said in a telephone interview. "We don't know how it translates in humans until we test human antibodies in clinical trials."

Indeed, there have been scores of mice that were cured of cancer and other diseases with experimental drugs that did not work in humans.

But Lilly is excited about this study because, at least in mice, a new therapeutic approach for Alzheimer's disease appears to be viable.

DeMattos said the drugmaker, which is developing other Alzheimer's drugs, is already engineering a human antibody that will target insoluble plaques. He said he expects the company to begin clinical trials using this antibody within a year.

Results of the study, entirely funded by Lilly, were published in the journal Neuron on Wednesday.

Lilly's best known Alzheimer's disease drug is solanezumab, a medicine given by infusion that attacks amyloid beta protein. In data presented in August, the drug failed in large clinical trials to arrest cognitive and physical declines among patients with mild to moderate Alzheimer's. But it was shown to somewhat delay cognitive declines in patients with mild symptoms.
Read More..

U.S. House Democrats introduce new meningitis legislation

WASHINGTON (Reuters) - Two Democratic lawmakers in the U.S. House of Representatives introduced legislation on Wednesday aimed at bolstering federal oversight of compounded drugs like the tainted steroid injections blamed for a deadly fungal meningitis outbreak.

But the legislation is not likely to move forward in the Republican-controlled chamber. In fact, aides from both parties said neither the House nor the Democratic-led Senate is expected to vote on meningitis legislation this year, given the little time remaining and the overarching focus on so-called "fiscal cliff" deficit-reduction talks.

Some Democratic lawmakers have warned that enacting tighter federal standards for compounded drugs could become more difficult in the new year, as the meningitis outbreak wanes and loses public attention.

The outbreak, linked to steroid injections from the Massachusetts-based New England Compounding Center, has sickened 541 people, 36 of whom have died, according to the U.S. Centers for Disease Control and Prevention.

The public health disaster has also spawned several investigations including a U.S. grand jury probe.

Drug compounding is a traditional pharmacy practice in which pharmacists alter or recombine drugs to meet the special needs of individual patients with a physician's prescription. The practice is regulated mainly by state pharmacy boards that do not impose the stringent safety and efficacy standards that the Food and Drug Administration requires of drug manufacturers.

But in the past few decades, some compounding pharmacies, such as NECC, have become large operations selling thousands of drug doses to clinics, hospitals and other healthcare providers across state lines.

Critics say those operations rival drug manufacturers in scale and should be subjected to strict FDA standards. But past attempts to strengthen federal regulation has been defeated by industry lobbying and legal maneuvering.

FDA has lately come under fire in Congress, mainly from Republican lawmakers who say it has the authority to act against problem compounders but failed to take effective action against NECC despite problems dating back ten years.

Public Citizen, an advocacy group that tracks drug safety issues, has called for an investigation of FDA's failures and urged the agency to inspect other compounders where problems have also surfaced over the past several years.

The legislation introduced on Wednesday by Democratic representatives Rosa DeLauro of Connecticut and Nita Lowery of New York is the second House Democratic measure to emerge since the outbreak first surfaced in mid-September.

The bill, known as the SAFE Compounding Drugs Act, would require compounding companies to register with the FDA, allow the agency to set minimum production standards and impose new labeling restrictions on compounded drugs.

Representative Ed Markey, a Democrat from Massachusetts, also introduced a measure to address FDA's authority last month.

The agency itself has called on Congress to allow it to set national standards for large drug compounding operations. FDA officials are scheduled to discuss a potential new regulatory structure during a meeting with state officials on December 19.
Read More..

Pfizer breast cancer drug delays progression 18 months

(Reuters) - An experimental drug showed impressive effectiveness and safety in a mid-stage trial against a common form of advanced breast cancer, lifting Pfizer Inc shares nearly 2 percent.

The favorable results prompted the drugmaker to plan large late-stage trials of the drug next year. If approved, the medicine could fetch multi-billion dollar sales, industry analysts said.

The drug, called PD-0332991, delayed by more than 18 months the worsening of symptoms for postmenopausal women with the most common form of breast cancer. Data from the study of the drug was presented on Wednesday at the annual San Antonio Breast Cancer Symposium.

The medicine, which blocks enzymes known as CDK4 and 6 kinases, was taken in combination with a standard drug called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of breast cancer cases.

Patients had either locally advanced tumors or cancer that had spread to other parts of the body.

Those taking both drugs went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not PD-0332991. The 18.6 month difference was considered statistically significant.

"In a disease where a several-month improvement in progression-free survival is considered impressive, we view an 18.6-month improvement in PFS as remarkable," said analyst Jon LeCroy of MKM Partners. He predicted Pfizer will introduce the medicine in 2017.

Letrozole is the chemical name of Femara, a Novartis drug that belongs to a class of treatments called aromatase inhibitors that block production of estrogen.

Side effects seen in patients taking the drug combination included anemia, fatigue and neutropenia - a decline in white blood cells called neutrophils that can put patients at higher risk of infection.

"If approved in a front-line breast cancer setting, this drug has the potential to generate $2 billion to $6 billion" in worldwide sales for these types of breast cancer patients, said Mark Schoenebaum, an analyst with ISI Group, of PD-0332991.

Schoenebaum, who had not previously predicted any revenue for the drug, said the medicine could provide considerable "upside" to Pfizer revenue if it is cleared by regulators.

He noted that researchers have not yet disclosed to what degree the Pfizer drug might have prolonged patient survival.

Pfizer had released some data from the trial in May, but released updated findings on Wednesday.

Shares of Pfizer closed up 46 cents, or 1.8 percent, at $25.64 on the New York Stock Exchange on Wednesday.
Read More..

Dueling Fiscal Cliff Deceptions

A fog of misinformation has settled on the fiscal cliff, as both House Speaker John Boehner and Treasury Secretary Timothy Geithner have traded conflicting, misleading and false statements in recent days on the president’s deficit-reduction plan:

    * Geithner falsely claimed on “Fox News Sunday” that the president’s proposals to slow Medicare growth are “not shifting costs to seniors.” There are four proposals that would increase costs to some seniors by $32.9 billion over 10 years, beginning in 2017, including higher premiums and new fees and surcharges.
    * Boehner, also on Fox News, wrongly stated that the administration has proposed “$400 billion worth of unspecified cuts.” The administration has itemized nearly $600 billion worth of what it calls “cuts and reforms to mandatory programs” — half of that from Medicare.
    * Geithner exaggerates when he says the ratio of spending cuts to tax increases is “roughly 2 to 1.” The administration’s $3 trillion in “spending cuts” includes more than $800 billion on two wars financed by deficit spending and already set to end, and tens of billions in new or higher fees and surcharges described as “reforms.”
    * Boehner and other GOP leaders claimed in a letter to Obama that the president’s “proposal calls for $1.6 trillion in new tax revenue, twice the amount you supported during the campaign.” But the fact is that Obama’s fiscal 2013 budget proposal calls for $1.6 trillion in new tax revenues — which his opponent, Mitt Romney, attacked during the campaign.
    * Boehner repeatedly (and falsely) says the president’s fiscal 2013 budget plan will create “trillion-dollar deficits for as far as the eye can see.” It’s true the fiscal 2013 deficit is projected to be close to $1 trillion, but annual deficits would fall each year thereafter — dropping to $488 billion by Obama’s final year in 2017.

There is also much confusion on what exactly is in the president’s plan — despite Geithner’s briefing to Republican leaders and their staffs on Nov. 29.

Boehner says the administration has proposed more in new stimulus spending than it proposes in spending cuts. His office says the new stimulus spending could exceed $600 billion but the president proposes only $400 billion in spending cuts. The administration tells us that the stimulus package would not exceed $200 billion.

Obama’s Plan: Neither Painless nor Lacking Specifics

Geithner and Boehner have been the point men for their respective sides of the fiscal cliff debate.

Geithner briefed Republican leaders on Nov. 29 and made multiple TV appearances on Dec. 2 to talk about the president’s plan — which we detail in our Nov. 30 article, “Facing Facts on Fiscal Cliff.”

Geithner and Boehner both appeared on “Fox News Sunday” and each provided misleading information about the Obama administration’s proposed plan.

Geithner claimed that the president’s deficit reduction plan is about “strengthening Medicare, not shifting costs to seniors.” However, the president’s plan does shift some costs to seniors — mostly to higher-income beneficiaries, but also for all new beneficiaries.

There are four proposals, contained in both the president’s 2011 deficit-reduction plan and his fiscal 2013 budget, that would increase costs to seniors by $32.9 billion over 10 years. All four proposals would begin in 2017 — after Obama leaves office:

    * Expanded means testing for Medicare Parts B and D Premiums. The administration proposes to increase premiums under Medicare Part B (medical insurance) and D (prescription drugs) for higher-income seniors by 15 percent and freeze the high-income thresholds at current levels “until 25 percent of beneficiaries under parts B and D are subject to these premiums.” In 2012, only 5.1 percent of Part B enrollees and 3 percent of Part D enrollees pay higher premiums based on income, according to the Kaiser Family Foundation. The current thresholds for higher premiums are $85,000 for individuals and $170,000 for couples. Kaiser estimates that the income thresholds for paying higher premiums by 2035 will be equivalent to about $47,000 for individuals and $94,000 for couples “in today’s adjusted inflation dollars.” Cost to seniors: $28 billion over 10 years (pages 34-35).
    * Increased Medicare Part B deductible for new beneficiaries. The administration would increase the deductibles paid by new beneficiaries by $25 in 2017, 2019 and 2021. Cost to seniors: $2 billion over 10 years (page 35).
    * A copay for Medicare home-health care for new beneficiaries. There’s currently no copay. This proposal would create a new copay of $100 for each “home health episode.” Cost to seniors: $350 million over 10 years (page 35).
    * Medicare Part B premium surcharge for new beneficiaries who purchase Medigap coverage. The administration would impose a Part B premium surcharge for new beneficiaries who purchase “near first-dollar Medigap coverage.” Medigap policies cover Medicare’s out-of-pocket expenses, such as copays and deductibles. The administration’s plan says Medigap provides “less incentive” to make cost-efficient health care decisions. Cost to seniors: $2.5 billion over 10 years (page 35).

As he made the rounds of the other Sunday talk shows, Geithner gave an accurate — but incomplete — accounting of the president’s Medicare proposals. On “Meet the Press,” for example, Geithner said that “we’re proposing to modestly increase premiums for high income beneficiaries of Medicare.” But he did not mention that the president’s plan also raises costs for all new beneficiaries, not just those with high incomes.

For his part, Boehner twice criticized the administration for failing to provide detailed cuts, claiming the administration “put $400 billion worth of unspecified cuts that they’d be willing to talk about.” Geithner said that’s not true, claiming the administration has “proposed $600 billion of detailed reforms and savings, to our health care and other government programs.”

Boehner is wrong.

The president’s deficit-reduction plan, as proposed to Congress in September 2011, itemizes “nearly $580 billion in cuts and reforms to mandatory programs, of which $320 billion is savings from Federal health programs such as Medicare and Medicaid.” Those proposals are also listed in the president’s fiscal 2013 budget proposal in a section, beginning on page 23, titled “Cutting Waste, Reducing the Deficit.”

The Medicare proposals, for example, are a mix of reduced payments to certain providers, including teaching hospitals and post-acute care facilities — as well as the higher premiums and new fees for certain beneficiaries that we mentioned above.

White House spokesman Jay Carney made this point at a press briefing on the day of Geithner’s meeting with Republican leaders.
Read More..

Longer tamoxifen use cuts breast cancer deaths

Breast cancer  patients taking the drug tamoxifen can cut their chances of having the disease come back or kill them if they stay on the pills for 10 years instead of five years as doctors recommend now, a major study finds.

The results could change treatment, especially for younger women. The findings are a surprise because earlier research suggested that taking the hormone-blocking drug for longer than five years didn't help and might even be harmful.

In the new study, researchers found that women who took tamoxifen for 10 years lowered their risk of a recurrence by 25 percent and of dying of breast cancer by 29 percent compared to those who took the pills for just five years.

In absolute terms, continuing on tamoxifen kept three additional women out of every 100 from dying of breast cancer within five to 14 years from when their disease was diagnosed. When added to the benefit from the first five years of use, a decade of tamoxifen can cut breast cancer mortality in half during the second decade after diagnosis, researchers estimate.

Some women balk at taking a preventive drug for so long, but for those at high risk of a recurrence, "this will be a convincer that they should continue," said Dr. Peter Ravdin, director of the breast cancer program at the UT Health Science Center in San Antonio.

He reviewed results of the study, which was being presented Wednesday at a breast cancer conference in San Antonio and published by the British medical journal Lancet.

"The result of this trial will have a major, immediate impact on premenopausal women," Ravdin said.

About 50,000 of the roughly 230,000 new cases of breast cancer in the United States each year occur in women before menopause. Most breast cancers are fueled by estrogen, and hormone blockers are known to cut the risk of recurrence in such cases.

Tamoxifen long was the top choice, but newer drugs called aromatase inhibitors — sold as Arimidex, Femara, Aromasin and in generic form — do the job with less risk of causing uterine cancer and other problems.

But the newer drugs don't work well before menopause. Even some women past menopause choose tamoxifen over the newer drugs, which cost more and have different side effects such as joint pain, bone loss and sexual problems.

The new study aimed to see whether over a very long time, longer treatment with tamoxifen could help.

Dr. Christina Davies of the University of Oxford in England and other researchers assigned 6,846 women who already had taken tamoxifen for five years to either stay on it or take dummy pills for another five years.

Researchers saw little difference in the groups five to nine years after diagnosis. But beyond that time, 15 percent of women who had stopped taking tamoxifen after five years had died of breast cancer versus 12 percent of those who took it for 10 years. Cancer had returned in 25 percent of women on the shorter treatment versus 21 percent of those treated longer.

Tamoxifen had some troubling side effects: Longer use nearly doubled the risk of endometrial cancer. But it rarely proved fatal, and there was no increased risk among premenopausal women in the study — the very group tamoxifen helps most.

"Overall the benefits of extended tamoxifen seemed to outweigh the risks substantially," Dr. Trevor Powles of the Cancer Centre London wrote in an editorial published with the study.

The study was sponsored by cancer research organizations in Britain and Europe, the United States Army, and AstraZeneca PLC, which makes Nolvadex, a brand of tamoxifen, which also is sold as a generic for 10 to 50 cents a day. Brand-name versions of the newer hormone blockers, aromatase inhibitors, are $300 or more per month, but generics are available for much less.

The results pose a quandary for breast cancer patients past menopause and those who become menopausal because of their treatment — the vast majority of cases. Previous studies found that starting on one of the newer hormone blockers led to fewer relapses than initial treatment with tamoxifen did.

Another study found that switching to one of the new drugs after five years of tamoxifen cut the risk of breast cancer recurrence nearly in half — more than what was seen in the new study of 10 years of tamoxifen.

"For postmenopausal women, the data still remain much stronger at this point for a switch to an aromatase inhibitor," said that study's leader, Dr. Paul Goss of Massachusetts General Hospital. He has been a paid speaker for a company that makes one of those drugs.

Women in his study have not been followed long enough to see whether switching cuts deaths from breast cancer, as 10 years of tamoxifen did. Results are expected in about a year.

The cancer conference is sponsored by the American Association for Cancer Research, Baylor College of Medicine and the UT Health Science Center.
Read More..